3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Ovarian Neoplasms
29
Fallopian Tube Neoplasms
15
Breast Neoplasms
10
Carcinoma, Ovarian Epithelial
6
Peritoneal Neoplasms
3
Multiple Myeloma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Kaposi
1
Pelvic Neoplasms
1
Neoplasms, Plasma Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Low Grade Serous Ovarian Cancer
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Genital Neoplasms, Female
1
Genetic Predisposition to Disease
1
Endometrial Neoplasms
1
Carcinoma
1
Acquired Immunodeficiency Syndrome
1
AIDS-related Kaposi sarcoma
1
Interventions
pembrolizumab
95
Cisplatin
35
Paclitaxel
27
Carboplatin
27
Docetaxel
17
lenvatinib
15
Fluorouracil
14
Saline Solution
13
Capecitabine
12
Pemetrexed
10
Gemcitabine
10
Oxaliplatin
9
Cetuximab
7
Albumin-Bound Paclitaxel
7
olaparib
6
epacadostat
6
Bevacizumab
6
130-nm albumin-bound paclitaxel
6
Leucovorin
5
enzalutamide
4
Etoposide
4
trifluridine tipiracil drug combination
3
regorafenib
3
belzutifan
3
Prednisone
3
Irinotecan
3
Glucose
3
Dexamethasone
3
liposomal doxorubicin
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
liposomal doxorubicin
×
Clear all
NCT06312176
2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,200 enrolled
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled